COMBINING THE HDAF TRANSGENE WITH THE GP IIB/ IIIA INHIBITOR TIROFIBAN IMPROVES HEART PERFORMANCE AND REDUCES MYOCARDIAL DAMAGE FOLLOWING HYPERACUTE REJECTION IN AN EX VIVO PERFUSION MODEL

2004 ◽  
Vol 78 ◽  
pp. 573-574
Author(s):  
U Brandl ◽  
M Erhardt ◽  
H Jöckle ◽  
S Michel ◽  
I Bittmann ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Myocardial Damage ◽  
Hyperacute Rejection ◽  
Ex Vivo Perfusion ◽  
Perfusion Model ◽  
Heart Performance

An ex vivo Perfusion Model to Evaluate Hyperacute Rejection in a Discordant Pig-to-Human Combination

1998 ◽  
Vol 30 (5) ◽  
pp. 341-351 ◽  
Author(s):  
A.E. Fiane ◽  
V. Videm ◽  
A. Foerster ◽  
T. Scholz ◽  
T.H. Perdersen ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Hyperacute Rejection ◽  
Ex Vivo Perfusion ◽  
Perfusion Model

Prostanoid Release from Ex Vivo Perfused Canine Arteries and Veins: Effects of Prolonged Perfusion, Intermittent Perfusion, as well as Exposure to Exogenous Arachidonic Acid, Thrombin and Bradykinin

1989 ◽  
Vol 62 (03) ◽  
pp. 1034-1039 ◽  
Author(s):  
Jan S Brunkwall ◽  
James C Stanley ◽  
Timothy F Kresowik ◽  
Linda M Graham ◽  
William E Burkel ◽  
...  
Keyword(s):  
Arachidonic Acid ◽  
Ex Vivo ◽  
Fold Increase ◽  
Ex Vivo Perfusion ◽  
Cyclooxygenase Activity ◽  
Perfusion Model ◽  
Prostanoid Production ◽  
Slow Decline ◽  
Arteries And Veins ◽  
Nonpulsatile Flow

SummaryRegulation of prostanoid release from ex vivo perfused vessel segments is not fully understood. A series of perfusion experiments were performed with canine arteries and veins to define certain regulatory phenomena. Arteries were perfused with pulsatile flow of 90 ml/min at a pressure of 100 mmHg, and veins with nonpulsatile flow of 90 ml/min at a pressure of 7 mmHg. Segments were perfused with Hanks' balanced salt solution for five 15-min periods with the perfusate exchanged after each study period. With onset of perfusion, there was an initial burst of prostacyclin release to 127 ± 40 pg/mm2, declining to 32 ± 10 pg/mm2 after 60 minutes (p <0.005). If perfusion continued for 5.5 hours, there was a stable release period between 1 and 3 hours, followed by a very slow decline. At that time addition of arachidonic acid (AA) increased prostacyclin release six-fold (p <0.01). Vessels perfused for 1 hour and then rested for another hour, responded to reperfusion at the second onset of flow with a two-fold increase in prostacyclin release (p <0.01). Vessels perfused with thrombin, bradykinin or A A (either added to each perfusate or only to the last perfusate) exhibited greater prostacyclin release than did control segments. Release of thromboxane steadily declined with time in all parts of the study, and only increased with the addition of A A to the perfusate. These data indicate that vessel segments subjected to ex vivo perfusion do not maximally utilize enzyme systems responsible for prostanoid production, and after 1 hour perfusion have not depleted their phospholipids, and maintain functioning levels of phospholipase and cyclooxygenase activity. This perfusion model allows for the study of prostacyclin and thromboxane release from arteries and veins and their response to various drugs and other stimuli.

An Ex Vivo Perfusion Model To Study the Treatment of Thrombotic Microangiopathy during Pig-to-Human Xenogenic Kidney Transplantation.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3190-3190
Author(s):  
Wolf Ramackers ◽  
Lars Friedrich ◽  
Wolfgang Schüttler ◽  
Sabine Bergmann ◽  
Arnold Ganser ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Histological Examination ◽  
Thrombotic Microangiopathy ◽  
Flow Resistance ◽  
Ex Vivo ◽  
Autologous Blood ◽  
Human Kidney ◽  
Pharmacological Intervention ◽  
Ex Vivo Perfusion ◽  
Perfusion Model

Abstract Early rejection of xenogenic organs is associated with thrombotic microangiopathy and changes of coagulation resembling disseminated intravascular coagulation (DIC). Here, we used an ex vivo perfusion circuit as a model of pig-to-human kidney transplantation to study the nature and treatment of this pathology. Porcine kidneys were obtained following in situ cold perfusion with HTK organ preservation solution and immediately connected to a perfusion circuit containing porcine (“autologous”) or human (“xenogenic”) AB blood supplemented with complement component C1 inhibitor (1 U/ml) and heparin (1 U/ml). Perfusion of porcine kidneys with autologous blood was feasible for >240 min in all experiments. In contrast, perfusion of porcine kidneys with xenogenic human blood was limited by a dramatic increase of flow resistance after 30 to 240 min. Increased concentrations of C3a as a marker for complement activation were associated with early perfusion failure. In addition, a dramatic increase of thrombin-antithrombin complex (TAT) and D Dimer (DD) was observed together with consumption of platelets, fibrinogen and antithrombin (AT). Histological examination demonstrated extensive thrombotic microangiopathy. Supplementation recombinant human activated protein C (rhAPC, 300 ug/l*h, n=3) or recombinant human antithrombin (rhAT, 3 U/ml, n=3) abolished the increase of flow resistance and allowed for a xenogenic kidney survival of >240 min in all experiments. Increase of DD was abolished and the consumption of fibrinogen was abrogated by both treatments as compared to control, whereas the increase of TAT was abolished only by rhAPC. Histological examination revealed no evidence of thrombotic microangiopathy for both treatments as compared to control. In conclusion, the perfusion model introduced here is a suitable tool for studying coagulopathy during early rejection in xenotransplantation. Thrombotic microangiopathy and DIC-like activation of coagulation is associated with an increased flow resistance and failure of perfusion in this model. Pharmacological intervention such as the supplementation of rhAPC or rhAT can be studied using this model and has been shown to prevent coagulopathy and thrombotic microangiopathy.

C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model

1999 ◽  
Vol 42 (1-3) ◽  
pp. 231-243 ◽  
Author(s):  
Arnt E Fiane ◽  
Vibeke Videm ◽  
Harald T Johansen ◽  
Ove J Mellbye ◽  
Erik W Nielsen ◽  
...  
Keyword(s):  
Platelet Activation ◽  
Ex Vivo ◽  
Hyperacute Rejection ◽  
C1 Inhibitor ◽  
Perfusion Model

CURCUMIN ENHANCES LIVER PRESERVATION BY UNIVERSITY OF WISCONSIN SOLUTION IN AN EX-VIVO PERFUSION MODEL

1999 ◽  
Vol 67 (9) ◽  
pp. S649
Author(s):  
Thomas D. Johnston ◽  
Kunam S. Reddy ◽  
Gaughan Wu ◽  
Changgou Chien ◽  
Molky Nagabhusan ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Liver Preservation ◽  
University Of Wisconsin Solution ◽  
Ex Vivo Perfusion ◽  
University Of Wisconsin ◽  
Perfusion Model ◽  
Wisconsin Solution

325-I * ELASTIC PROPERTIES OF THE JUVENILE AORTA: NEW INSIGHTS FROM A NOVEL PORCINE EX-VIVO PERFUSION MODEL

2014 ◽  
Vol 19 (suppl 1) ◽  
pp. S97-S97
Author(s):  
T. Kruger ◽  
A. Grigoraviciute ◽  
K. Veseli ◽  
D. Schibilsky ◽  
H. P. Wendel ◽  
...  
Keyword(s):  
Elastic Properties ◽  
Ex Vivo ◽  
Ex Vivo Perfusion ◽  
Perfusion Model

scholarly journals Off-pump tricuspid valve repair by automated sutured tricuspid annular plication via transatrial cannulation: preclinical ex vivo and in vivo results

2019 ◽  
Vol 30 (4) ◽  
pp. 636-645
Author(s):  
Paul Werner ◽  
Marco Russo ◽  
Jude Sauer ◽  
Robert Zilberszac ◽  
Claus Rath ◽  
...  
Keyword(s):  
Minimally Invasive ◽  
Tricuspid Valve ◽  
Human Heart ◽  
Ex Vivo ◽  
Invasive Technique ◽  
Tricuspid Valve Repair ◽  
Off Pump ◽  
Ex Vivo Perfusion ◽  
Perfusion Model

Abstract OBJECTIVES Surgical repair is considered the gold standard treatment for severe symptomatic tricuspid valve (TV) regurgitation. However, patients undergoing isolated surgical tricuspid repair face a high perioperative mortality while long-term data on interventional treatment options are currently missing. We investigated a novel, minimally invasive approach for transatrial off-pump beating-heart tricuspid annular plication based on the surgical Hetzer repair. METHODS TV annular plication for the creation of a double-orifice valve using novel devices for automated annular suturing was performed in 10 human heart specimens in an ex vivo perfusion model under endoscopic guidance. Additionally, the technique was tested in an in vivo porcine model using the transatrial access under echocardiographic and fluoroscopic guidance. RESULTS Endoscopically guided conduction of the procedure was successful in all 10 human heart specimens in the ex vivo perfusion model with 1 observed suture pull-through of 60 sutures placed (1.7%). TV measurements yielded significant reductions of the TV septal–lateral diameter (50.9 ± 7.3 vs 42.6 ± 7.9 mm; P = 0.015) and the TV area (1208 ± 399 vs 193 ± 122 mm2; P &lt; 0.0001). TV plication without direct vision using device-embedded intracardiac echocardiography, epicardial echocardiography and fluoroscopy was feasible in both acute animals with no observed device-related adverse events. CONCLUSIONS Successful plication was completed in 10 ex vivo human hearts, additionally proof-of-concept was conducted in 2 animals. We herein present encouraging early preclinical results of a novel minimally invasive technique for TV repair, which warrants further investigation.

scholarly journals Abstract No. 130 Evaluation of an experimental radiopaque microsphere in an ex vivo perfusion model

2021 ◽  
Vol 32 (5) ◽  
pp. S58
Author(s):  
R. Bitar ◽  
L. Garza ◽  
Matt Parker ◽  
C. Ortiz ◽  
R. Suri ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Ex Vivo Perfusion ◽  
Perfusion Model
Sign in / Sign up

Export Citation Format

Share Document